Science & Tech · AI · 3 hrs ago
China approves first original drug developed with AI assistance
China approved its first original drug developed with AI assistance in September.
The drug, called Aipuswei, was developed by Westlake University and other institutions.
Its path from discovery through clinical trials took three and a half years, compared with the decade often associated with traditional drug development.
AI helped researchers search huge pools of chemical compounds and predict safety risks, speeding up early stages of the work.
Faster screening does not mean more drugs will succeed: candidates still need extensive testing, and experts warn that more AI-generated molecules can also mean more failures.
The next challenge is to test candidates effectively, using reliable, standardized data and evidence that a medicine helps patients.
China’s latest five-year plan for the pharmaceutical industry calls for systems to collect and track data across AI-assisted drug development, and sets targets for the sector by 2030.
China approved its first original drug developed with AI assistance in September 2026.
The drug, istarvir hydrochloride tablets, is marketed under the name Aipusiwei and was developed by Westlake University and other organizations.
Its development from initial discovery through clinical trials took three and a half years, according to the article.
AI helped screen more than 100 million compounds and improve predictions about safety and toxicity.
Experts said faster early-stage research does not necessarily mean a higher rate of successful drug development.
- Who
- Westlake University and other organizations developed the drug.
- What
- China approved its first original drug developed with AI assistance, istarvir hydrochloride tablets, marketed as Aipusiwei.
- When
- It was approved in September 2026.
- Where
- China.
- Why
- Not stated
AI proponents
AI development skeptics
Research efficiency
AI proponents
AI helped screen compounds and improve safety and toxicity predictions.
AI development skeptics
Faster generation of drug candidates does not necessarily reduce failures in later development.
Potential value
AI proponents
AI could reshape research and help scientists identify new disease mechanisms and drug targets.
AI development skeptics
Its value should be judged by whether it improves success rates, clinical outcomes and patient benefit.
Development from initial discovery through clinical trials took three and a half years.
China approved istarvir hydrochloride tablets, marketed as Aipusiwei.
- Drug
- Istarvir hydrochloride tablets, marketed as Aipusiwei
- Approval
- September 2026
- Development period
- Three and a half years from initial discovery through clinical trials
- Virtual screening
- More than 100 million compounds
- Developers
- Westlake University and other organizations
1 source
What people are saying
The more molecules generated, the more failures there are.
Aipusiwei proves that AI-assisted drug research and development is efficient and feasible at present.
AI’s real new change is not an upgrade in computing power, but a reshaping of the research paradigm.